 |
 Video: What is a Stock Split?
|
|
|
| Pharvaris is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Co.'s first molecule, PHA121, is a small-molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema, or HAE. PHA121 has been observed to be a potent inhibitor in vitro as assessed using human recombinant bradykinin B2 receptors (150 pM); ex vivo as studied against endogenous bradykinin B2 receptors in a human umbilical vein model (350 pM); and in vivo in the human bradykinin-challenge model (170 pM). According to our Pharvaris stock split history records, Pharvaris has had 0 splits. | |
|
Pharvaris (PHVS) has 0 splits in our Pharvaris stock split history database.
Looking at the Pharvaris stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Pharvaris shares, starting with a $10,000 purchase of PHVS, presented on a split-history-adjusted basis factoring in the complete Pharvaris stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/08/2021 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$28.70 |
|
| End price/share: |
$23.53 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-18.01% |
|
| Average Annual Total Return: |
-5.97% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$8,198.23 |
|
| Years: |
3.23 |
|
|
|
|
|
